The first large scale human clinical trial in patients with relapsing-remitting MS (RRMS) using interferon beta (IFN-β) was published in 1993 and showed that relapse rates were reduced by 34% in high dose IFN-β1b and by 8% in lower dose compared to placebo group, and severity of relapses was also reduced (6). This evidence concerns the gene IFNA1 and relapsing-remitting multiple sclerosis.